Evidence map›Paper›PMID 35285252›Full record

ArticleAntimicrobial agents and chemotherapy2022

Li-Hua Li, Hsu-Feng Lu, Yi-Fu Liu, Yi-Tsung Lin, Tsuey-Ching Yang

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Versatility ofHeliyon · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Li-Hua Li *Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospitalgrid.278247.c, Taipei, Taiwan.
Hsu-Feng Lu *Department of Medical Laboratory Science and Biotechnology, Asia University, Taichung, Taiwan.
Yi-Fu LiuDepartment of Biotechnology and Laboratory Science in Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Yi-Tsung LinDivision of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospitalgrid.278247.c, Taipei, Taiwan.
Tsuey-Ching YangDepartment of Biotechnology and Laboratory Science in Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.ORCID 0000-0003-4111-6870
National Yang Ming Chiao Tung University · TWAsia University · TWTaipei Veterans General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pathogenic bacteria experience diverse stresses induced by host cells during infection and have developed intricate systems to trigger appropriate responses. Bacterial stress responses have been reported to defend against these stresses and cross-protect bacteria from antibiotic attack. In this study, we aimed to assess whether oxidative stress affects bacterial susceptibility to fluoroquinolone (FQ) and the underlying mechanism. Stenotrophomonas maltophilia, a species with high genetic diversity, is distributed ubiquitously and is an emerging multidrug-resistant opportunistic pathogen. FQs are among the limited antibiotic treatment options for S. maltophilia infection. The minimum inhibitory concentrations (MICs) of 103 S. maltophilia clinical isolates against ciprofloxacin (CIP) and levofloxacin (LVX) were determined using the agar dilution method in Mueller-Hinton plates with or without menadione (MD), a superoxide generator. The resistance rates for ciprofloxacin and levofloxacin were 40% and 18% in the MD-null group and increased to 91% and 23%, respectively, in the MD-treated group. Of the 103 isolates tested, 54% and 27% had elevated MICs against ciprofloxacin and levofloxacin, respectively, in the presence of MD. The involvement of oxidative stress responses in the MD-mediated FQ resistance was further assessed by mutants construction and viability assay. Among the 16 oxidative stress alleviation systems evaluated,

Indexed as

Gram-Negative Bacterial InfectionsStenotrophomonas maltophiliaAnti-Bacterial AgentsCiprofloxacinFluoroquinolonesHumansLevofloxacinMicrobial Sensitivity TestsOxidative StressAnti-Bacterial AgentsCiprofloxacinFluoroquinolonesLevofloxacinantimicrobial susceptibility testfluoroquinolone resistanceoxidative stressStenotrophomonas maltophilia

Identifiers

PMID35285252
PMCPMC9017363
OpenAlexW4220868333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.